https://www.biopharmawatch.com/news/GILD/fda-approves-gileads-bixlenvo-hiv-treatment BiopharmaWatch en 2026-08-27T21:47:00.000Z U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens https://www.biopharmawatch.com/news/SGP/spyglass-pharma-irvine-headquarters-opening BiopharmaWatch en 2026-08-27T20:40:00.000Z SpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space https://www.biopharmawatch.com/news/BNTX/pfizer-biontech-fda-approval-xfg-covid-vaccine BiopharmaWatch en 2026-08-27T20:30:29.000Z Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine https://www.biopharmawatch.com/news/PFE/pfizer-biontech-fda-approval-xfg-covid-vaccine BiopharmaWatch en 2026-08-27T20:30:00.000Z Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine https://www.biopharmawatch.com/news/IQV/iqvia-awards-ai-technology-innovation BiopharmaWatch en 2026-08-27T20:15:00.000Z IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare https://www.biopharmawatch.com/news/IMCC/im-cannabis-shares-trading-consolidated-basis BiopharmaWatch en 2026-08-27T20:10:00.000Z IM Cannabis Shares Commence Trading on 30:1 Consolidated Basis https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-public-offering BiopharmaWatch en 2026-08-27T20:09:00.000Z Kazia Therapeutics Limited Announces Proposed Public Offering https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-promotes-nick-smith-president-cfo BiopharmaWatch en 2026-08-27T20:05:00.000Z Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer https://www.biopharmawatch.com/news/QGEN/qiagen-launches-qiaysymphony-connect-nucleic-acid-extraction BiopharmaWatch en 2026-08-27T20:05:00.000Z QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction https://www.biopharmawatch.com/news/AGL/agilon-health-revised-presentation-time-jefferies-conference BiopharmaWatch en 2026-08-27T20:05:00.000Z agilon health Announces Revised Presentation Time at the 2026 Jefferies Healthcare Services and Technology Conference https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-appoints-kevin-lundquist-cfo BiopharmaWatch en 2026-08-27T20:05:00.000Z Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™ https://www.biopharmawatch.com/news/RMD/resmed-participation-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-08-27T20:05:00.000Z Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-paxalisib-triple-negative-breast-cancer BiopharmaWatch en 2026-08-27T20:01:00.000Z Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer https://www.biopharmawatch.com/news/HTFL/heartflow-wells-fargo-healthcare-conference-2026 BiopharmaWatch en 2026-08-27T20:01:00.000Z Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/ACET/adicet-bio-fda-clearance-adi-212 BiopharmaWatch en 2026-08-27T20:00:00.000Z Adicet Bio Announces FDA Clearance of IND Application for ADI-212 https://www.biopharmawatch.com/news/ROIV/roivant-fda-approval-lisraya-dermatomyositis BiopharmaWatch en 2026-08-27T19:29:00.000Z Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. https://www.biopharmawatch.com/news/PHG/philips-imricor-interventional-mr-lab-solution BiopharmaWatch en 2026-08-27T19:27:00.000Z Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration https://www.biopharmawatch.com/news/SYK/stryker-participate-2026-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-27T19:00:00.000Z Stryker to participate in the 2026 Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/ALGS/alg-055009-phase-2a-trial-non-cirrhotic-adults BiopharmaWatch en 2026-08-27T17:37:32.000Z ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial https://www.biopharmawatch.com/news/WAT/letsgetchecked-fuze-health-waters-hpv-screening-tool BiopharmaWatch en 2026-08-27T14:00:00.000Z LetsGetChecked Powered by Fuze Health Partners with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-names-six-broker-dealers-lawsuit BiopharmaWatch en 2026-08-27T13:27:00.000Z Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit https://www.biopharmawatch.com/news/QDEL/faster-answers-better-decisions-adlm-2026-highlights BiopharmaWatch en 2026-08-27T13:12:00.000Z Faster Answers, Better Decisions: ADLM 2026 Highlights https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-virtual-investor-conference BiopharmaWatch en 2026-08-27T13:06:29.000Z CNS Pharmaceuticals Participates in the Virtual Investor “Why Now” On-Demand Conference https://www.biopharmawatch.com/news/MYGN/myriad-genetics-presentation-wells-fargo-conference-2026 BiopharmaWatch en 2026-08-27T13:05:00.000Z Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/MBRX/moleculin-ceo-participates-virtual-investor-conference BiopharmaWatch en 2026-08-27T13:01:23.000Z Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference https://www.biopharmawatch.com/news/DARE/dare-bioscience-ceo-participates-virtual-investor-series BiopharmaWatch en 2026-08-27T13:01:00.000Z Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-virtual-investor-conference BiopharmaWatch en 2026-08-27T13:01:00.000Z Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference https://www.biopharmawatch.com/news/GRI/gri-bio-why-now-video-webcast BiopharmaWatch en 2026-08-27T13:01:00.000Z GRI Bio Featured in "Why Now" On-Demand Video Webcast https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-virtual-investor-conference BiopharmaWatch en 2026-08-27T13:01:00.000Z Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-ceo-bob-jahr-virtual-investor-conference BiopharmaWatch en 2026-08-27T13:01:00.000Z Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference https://www.biopharmawatch.com/news/AIM/aim-immunotech-participates-virtual-investor-conference BiopharmaWatch en 2026-08-27T13:01:00.000Z AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference https://www.biopharmawatch.com/news/CELU/celularity-musecell-us-manufacturing-collaboration BiopharmaWatch en 2026-08-27T13:00:00.000Z Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-hemodiafiltration-study BiopharmaWatch en 2026-08-27T13:00:00.000Z Fresenius Medical Care Announces Publication of a Multinational Real-World Evidence Study Associating High-Volume Hemodiafiltration with Lower Mortality Risk Than Conventional Hemodialysis https://www.biopharmawatch.com/news/CVS/cvs-pharmacy-minuteclinic-offering-updated-flu-vaccines BiopharmaWatch en 2026-08-27T13:00:00.000Z CVS Pharmacy® and MinuteClinic® now offering updated flu vaccines nationwide https://www.biopharmawatch.com/news/CALC/calcimedica-reverse-stock-split-2026 BiopharmaWatch en 2026-08-27T13:00:00.000Z CalciMedica Announces One-for-Five Reverse Stock Split https://www.biopharmawatch.com/news/FBRX/argenx-completes-acquisition-forte-biosciences BiopharmaWatch en 2026-08-27T12:50:00.000Z argenx Completes Acquisition of Forte Biosciences, Inc. https://www.biopharmawatch.com/news/CAI/caris-ai-guided-therapy-pancreatic-cancer-study BiopharmaWatch en 2026-08-27T12:30:00.000Z Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer https://www.biopharmawatch.com/news/PRGO/perrigo-attend-barclays-global-consumer-conference BiopharmaWatch en 2026-08-27T12:30:00.000Z Perrigo to Attend the Barclays Global Consumer Conference https://www.biopharmawatch.com/news/FBLG/fibrobiologics-cyw628-phase-1-2-trial-update BiopharmaWatch en 2026-08-27T12:30:00.000Z FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-preclinical-pancreatic-cancer-data BiopharmaWatch en 2026-08-27T12:30:00.000Z Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-hc-wainwright-conference-2026 BiopharmaWatch en 2026-08-27T12:30:00.000Z Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/BMRA/biomerica-announces-2-23-million-financing BiopharmaWatch en 2026-08-27T12:19:00.000Z Biomerica Announces $2.23 Million Financing https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-2026-cantor-conference BiopharmaWatch en 2026-08-27T12:05:00.000Z Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference https://www.biopharmawatch.com/news/BHC/bausch-health-2026-aspire-higher-scholarship-winners BiopharmaWatch en 2026-08-27T12:02:00.000Z Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-reverse-stock-split BiopharmaWatch en 2026-08-27T12:00:00.000Z Glucotrack, Inc. Announces Reverse Stock Split https://www.biopharmawatch.com/news/ARDT/ardent-health-wells-fargo-conference-2026 BiopharmaWatch en 2026-08-27T12:00:00.000Z Ardent Health to Participate in the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/XTNT/xtant-medical-biohorizons-partnership-prolifica BiopharmaWatch en 2026-08-27T12:00:00.000Z Xtant Medical Announces Exclusive Partnership with BioHorizons to Expand Access to Xtant's Allogeneic Growth Factor into the Dental Market https://www.biopharmawatch.com/news/ENTX/entera-participate-fall-investor-conferences BiopharmaWatch en 2026-08-27T12:00:00.000Z Entera to Participate in Upcoming Fall Investor Conferences https://www.biopharmawatch.com/news/PLUR/pluri-announces-3-3-million-offering BiopharmaWatch en 2026-08-27T12:00:00.000Z Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor https://www.biopharmawatch.com/news/VRCA/verrica-completes-enrollment-cove-2-trial-ychant BiopharmaWatch en 2026-08-27T12:00:00.000Z Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027 https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-esc-congress-2026-psvt-impact BiopharmaWatch en 2026-08-27T12:00:00.000Z Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes https://www.biopharmawatch.com/news/HQY/healthequity-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-27T12:00:00.000Z HealthEquity Reports Second Quarter Ended July 31, 2026 Financial Results https://www.biopharmawatch.com/news/MBX/mbx-biosciences-phase-3-optimize-trial-canjuparatide BiopharmaWatch en 2026-08-27T12:00:00.000Z MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism https://www.biopharmawatch.com/news/CTMX/cytomx-fda-fast-track-varseta-m-colorectal-cancer BiopharmaWatch en 2026-08-27T12:00:00.000Z CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) https://www.biopharmawatch.com/news/SLBT/sl-science-fda-drug-master-file-gdt-exosomes BiopharmaWatch en 2026-08-27T12:00:00.000Z SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform https://www.biopharmawatch.com/news/VTAK/catheter-precision-commercial-milestones-vtak BiopharmaWatch en 2026-08-27T12:00:00.000Z Catheter Precision Achieves Major Commercial Milestones with Cardinal Health, Johns Hopkins and the placement of the First VIVO System in Germany https://www.biopharmawatch.com/news/ALVO/alvotech-investor-conferences-september-2026 BiopharmaWatch en 2026-08-27T12:00:00.000Z Alvotech to present at upcoming investor conferences in September https://www.biopharmawatch.com/news/USPH/us-physical-therapy-midwest-ideas-conference-2026 BiopharmaWatch en 2026-08-27T11:30:00.000Z U.S. Physical Therapy Presented at the 17th Annual Midwest Ideas Conference https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-soquelitinib-phase-1-data BiopharmaWatch en 2026-08-27T11:30:00.000Z Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial https://www.biopharmawatch.com/news/BWAY/brainsway-deep-tms-suicidal-ideation-reduction BiopharmaWatch en 2026-08-27T11:30:00.000Z BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation https://www.biopharmawatch.com/news/NXL/nexalin-technology-reverse-stock-split BiopharmaWatch en 2026-08-27T11:25:00.000Z Nexalin Technology Announces Reverse Stock Split https://www.biopharmawatch.com/news/HLF/herbalife-fireside-chat-barclays-global-consumer-conference BiopharmaWatch en 2026-08-27T11:05:00.000Z Herbalife to Participate in Fireside Chat at Barclays Global Consumer Conference on September 9 https://www.biopharmawatch.com/news/AVAH/aveanna-participate-deutsche-bank-healthcare-summit BiopharmaWatch en 2026-08-27T11:00:00.000Z Aveanna to Participate in the Deutsche Bank 2026 Healthcare Summit https://www.biopharmawatch.com/news/NBP/novabridge-biosciences-september-investor-conferences BiopharmaWatch en 2026-08-27T11:00:00.000Z NovaBridge Biosciences to Participate in September Investor Conferences https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-participate-2026-wells-fargo-conference BiopharmaWatch en 2026-08-27T10:50:00.000Z Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/NTRA/natera-angiex-collaboration-signatera-agx101 BiopharmaWatch en 2026-08-27T10:00:00.000Z Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™ https://www.biopharmawatch.com/news/AMGN/tezspire-positive-phase-3-results-eosinophilic-esophagitis BiopharmaWatch en 2026-08-27T06:00:00.000Z TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS https://www.biopharmawatch.com/news/ABBV/abbvie-submits-ema-application-skyrizi-crohns-disease BiopharmaWatch en 2026-08-27T06:00:00.000Z AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-upsized-private-offering-notes BiopharmaWatch en 2026-08-27T04:30:00.000Z Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases https://www.biopharmawatch.com/news/MESO/mesoblast-reports-revenue-growth-2026 BiopharmaWatch en 2026-08-27T00:32:00.000Z Mesoblast Reports Substantial Revenue Growth to US$120M https://www.biopharmawatch.com/news/CUVL/clinuvel-nasdaq-listing-asx-delisting BiopharmaWatch en 2026-08-26T22:35:54.000Z CLINUVEL considers Nasdaq listing, ASX delisting https://www.biopharmawatch.com/news/CUVL/decade-profitability-clinuvel-us-expansion BiopharmaWatch en 2026-08-26T22:34:49.000Z A decade of profitability provides foundation for CLINUVEL’s U.S. expansion https://www.biopharmawatch.com/news/CUVL/clinuvel-appendix-4e-annual-report BiopharmaWatch en 2026-08-26T22:33:49.000Z Appendix 4E & Annual Report https://www.biopharmawatch.com/news/CUVL/clinuvel-investor-presentation-us-expansion BiopharmaWatch en 2026-08-26T22:32:49.000Z CLINUVEL Investor Presentation https://www.biopharmawatch.com/news/CUVL/appendix-4g-corporate-governance-statement BiopharmaWatch en 2026-08-26T22:32:00.000Z Appendix 4G and Corporate Governance Statement https://www.biopharmawatch.com/news/CUVL/dividend-distribution-cuv BiopharmaWatch en 2026-08-26T22:30:49.000Z Dividend/Distribution – CUV https://www.biopharmawatch.com/news/GMED/globus-medical-acquisition-higgs-boson-health BiopharmaWatch en 2026-08-26T21:57:00.000Z Globus Medical Announces Acquisition of Higgs Boson Health to Transform Healthcare Experience Through AI-Driven Digital Solutions https://www.biopharmawatch.com/news/IMRX/immuneering-fda-approval-pancreatic-cancer BiopharmaWatch en 2026-08-26T21:16:00.000Z Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients https://www.biopharmawatch.com/news/ALC/alcon-prices-eur-500-million-senior-notes-offering BiopharmaWatch en 2026-08-26T21:00:00.000Z Alcon Prices EUR 500 Million Senior Notes Offering https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-q4-fiscal-year-results BiopharmaWatch en 2026-08-26T20:20:00.000Z Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance https://www.biopharmawatch.com/news/NEO/neogenomics-medicare-coverage-radar-st-assay BiopharmaWatch en 2026-08-26T20:17:00.000Z NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring https://www.biopharmawatch.com/news/BDX/bd-presents-wells-fargo-healthcare-conference-2026 BiopharmaWatch en 2026-08-26T20:15:00.000Z BD to Present at Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/TRAX/first-tracks-biotherapeutics-september-investor-conferences BiopharmaWatch en 2026-08-26T20:15:00.000Z First Tracks Biotherapeutics Announces Participation in September Investor Conferences https://www.biopharmawatch.com/news/RXST/rxsight-participate-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-26T20:15:00.000Z RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/A/agilent-reports-third-quarter-fiscal-year-2026-results BiopharmaWatch en 2026-08-26T20:05:00.000Z Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results https://www.biopharmawatch.com/news/EYE/national-vision-participation-barclays-consumer-conference BiopharmaWatch en 2026-08-26T20:05:00.000Z National Vision, Inc. Announces Participation in Barclays 19th Annual Global Consumer Conference https://www.biopharmawatch.com/news/CNMD/conmed-participate-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-26T20:05:00.000Z CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-investor-conferences-september-2026 BiopharmaWatch en 2026-08-26T20:05:00.000Z Arcus Biosciences to Participate in Three Upcoming Investor Conferences https://www.biopharmawatch.com/news/GILD/gilead-sciences-investor-conferences-september-2026 BiopharmaWatch en 2026-08-26T20:05:00.000Z Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences https://www.biopharmawatch.com/news/XENE/xenon-phase-3-x-tole2-eec-2026 BiopharmaWatch en 2026-08-26T20:01:00.000Z Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026 https://www.biopharmawatch.com/news/VRTX/vertex-upcoming-september-investor-conferences BiopharmaWatch en 2026-08-26T20:00:00.000Z Vertex to Participate in Upcoming September Investor Conferences https://www.biopharmawatch.com/news/RVMD/fda-approves-revolution-medicines-rasonque-metastatic-pancreatic-cancer BiopharmaWatch en 2026-08-26T16:59:00.000Z U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer https://www.biopharmawatch.com/news/AGEN/agenus-nest-phase-2-publication-colon-cancer BiopharmaWatch en 2026-08-26T14:05:00.000Z Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer https://www.biopharmawatch.com/news/NTHI/neonc-clinical-results-neon100-brain-cancer BiopharmaWatch en 2026-08-26T13:39:00.000Z NeOnc’s Clinical Story Is Now the Main Event https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-presentation-wells-fargo-conference BiopharmaWatch en 2026-08-26T13:15:00.000Z Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/RFL/sofis-appoints-rafael-fraga-ceo BiopharmaWatch en 2026-08-26T13:00:00.000Z Sofis Announces Appointment of Rafael Fraga as CEO https://www.biopharmawatch.com/news/WAT/waters-corporation-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-26T13:00:00.000Z Waters Corporation to Present at the Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/FEMY/femasys-unc-health-fertility-portfolio BiopharmaWatch en 2026-08-26T13:00:00.000Z Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations https://www.biopharmawatch.com/news/MLSS/milestone-scientific-debt-free-balance-sheet BiopharmaWatch en 2026-08-26T13:00:00.000Z Milestone Scientific Achieves Debt-Free Balance Sheet Through Debt-to-Equity Conversion by Three Directors https://www.biopharmawatch.com/news/DARE/dare-bioscience-sildenafil-cream-menopause-study BiopharmaWatch en 2026-08-26T12:45:00.000Z Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society https://www.biopharmawatch.com/news/ONC/beone-medicines-fda-approval-tevimabra-treatment BiopharmaWatch en 2026-08-26T12:40:00.000Z Riassunto: BeOne Medicines annuncia l'approvazione da parte dell'FDA statunitense del regime a base di TEVIMBRA per il trattamento di prima linea dell'adenocarcinoma gastroesofageo (GEA) HER2-positivo https://www.biopharmawatch.com/news/ONC/beone-medicines-fda-approval-tevimbra-her2-gea BiopharmaWatch en 2026-08-26T12:40:00.000Z Samenvatting: BeOne Medicines kondigt goedkeuring door Amerikaanse FDA aan voor een op TEVIMBRA gebaseerd behandelregime bij eerstelijnsbehandeling van HER2+ GEA https://www.biopharmawatch.com/news/ONC/fda-approval-tevimbra-therapy-her2-positive-gea BiopharmaWatch en 2026-08-26T12:40:00.000Z BeOne Medicines gibt die Zulassung durch die US-amerikanische FDA für eine auf TEVIMBRA basierende Therapie zur Erstlinienbehandlung von HER2-positiver GEA bekannt https://www.biopharmawatch.com/news/CDIO/cardio-diagnostics-rural-cardiovascular-care-gap BiopharmaWatch en 2026-08-26T12:35:00.000Z Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-nasdaq-ld-micro-summit BiopharmaWatch en 2026-08-26T12:32:00.000Z Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit https://www.biopharmawatch.com/news/SPRC/scisparc-advances-agentic-ai-strategy-prof-carmel-domshlak BiopharmaWatch en 2026-08-26T12:32:00.000Z SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board https://www.biopharmawatch.com/news/AIDX/2020-biolabs-investor-webinar-september-2026 BiopharmaWatch en 2026-08-26T12:31:00.000Z 20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity https://www.biopharmawatch.com/news/ELAN/elanco-expansion-kansas-manufacturing-facility BiopharmaWatch en 2026-08-26T12:30:00.000Z Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility https://www.biopharmawatch.com/news/FBLG/fibrobiologics-regains-nasdaq-compliance BiopharmaWatch en 2026-08-26T12:30:00.000Z FibroBiologics Regains Compliance with Nasdaq Trading Rules https://www.biopharmawatch.com/news/IMNN/imunon-rd-day-phase-3-ovation-3-trial BiopharmaWatch en 2026-08-26T12:30:00.000Z IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001 https://www.biopharmawatch.com/news/NMAD/nomad-power-solutions-vermont-energy-storage-phase-3 BiopharmaWatch en 2026-08-26T12:30:00.000Z NOMAD Power Solutions, Inc. Receives DOE Authorization to Advance Vermont Long-Duration Energy Storage Project into Phase 3 https://www.biopharmawatch.com/news/CELC/celcuity-submits-snda-fda-revtorpyk-breast-cancer BiopharmaWatch en 2026-08-26T12:30:00.000Z Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer https://www.biopharmawatch.com/news/AMIX/autonomix-medical-us-patent-feedback-guided-therapy BiopharmaWatch en 2026-08-26T12:30:00.000Z Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery https://www.biopharmawatch.com/news/VNRX/volition-clinical-validation-nuq-nets-biomarker-sepsis BiopharmaWatch en 2026-08-26T12:17:00.000Z Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis https://www.biopharmawatch.com/news/HYPR/hyperfine-neurology-office-launch-momentum BiopharmaWatch en 2026-08-26T12:15:00.000Z Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans https://www.biopharmawatch.com/news/CADL/candel-therapeutics-september-investor-conferences BiopharmaWatch en 2026-08-26T12:05:00.000Z Candel Therapeutics to Present at September Investor Conferences https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-launch-mps3bstudy-com BiopharmaWatch en 2026-08-26T12:00:00.000Z Spruce Biosciences Announces Launch of MPS3BStudy.com https://www.biopharmawatch.com/news/OABI/omniab-participate-investor-conferences BiopharmaWatch en 2026-08-26T12:00:00.000Z OmniAb to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ODTX/odyssey-therapeutics-investor-conferences-september-2026 BiopharmaWatch en 2026-08-26T12:00:00.000Z Odyssey Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-esc-congress-2026-presentations BiopharmaWatch en 2026-08-26T12:00:00.000Z NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 https://www.biopharmawatch.com/news/INNV/innovage-conference-call-fiscal-2026-results BiopharmaWatch en 2026-08-26T12:00:00.000Z InnovAge Announces Conference Call to Discuss Fourth Quarter and Fiscal 2026 Financial Results and Participation in Upcoming Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-26T12:00:00.000Z Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/XERS/xeris-xp-8121-webinar-details BiopharmaWatch en 2026-08-26T11:30:00.000Z Xeris Announces Details for XP-8121 Program Overview Webinar https://www.biopharmawatch.com/news/RGEN/repligen-corporation-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-26T11:30:00.000Z Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-ers-congress-2026-presentations BiopharmaWatch en 2026-08-26T11:30:00.000Z Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026 https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-investor-conferences-september-2026 BiopharmaWatch en 2026-08-26T11:30:00.000Z Eikon Therapeutics to Participate in Investor Conferences in September 2026 https://www.biopharmawatch.com/news/PODD/insulet-participate-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-26T11:00:00.000Z Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-private-offering-exchangeable-notes BiopharmaWatch en 2026-08-26T11:00:00.000Z Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases https://www.biopharmawatch.com/news/INSM/insmed-september-2026-investor-conferences BiopharmaWatch en 2026-08-26T11:00:00.000Z Insmed to Present at September 2026 Investor Conferences https://www.biopharmawatch.com/news/INMB/inmune-bio-ebstrocel-eu-marketing-authorization BiopharmaWatch en 2026-08-26T11:00:00.000Z INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-doses-first-patient-phase-1-2a-trial BiopharmaWatch en 2026-08-26T11:00:00.000Z Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors https://www.biopharmawatch.com/news/KMTS/kestra-appoints-curtis-kopf-svp-customer-experience BiopharmaWatch en 2026-08-26T10:00:00.000Z Kestra Appoints Curtis Kopf as Senior Vice President of Customer Experience https://www.biopharmawatch.com/news/NBIX/neurocrine-fda-phase-2-nbi-1117567-alzheimers BiopharmaWatch en 2026-08-26T07:33:00.000Z Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition https://www.biopharmawatch.com/news/BHVN/biohaven-sk-biopharmaceuticals-licensing-agreement-opakalim BiopharmaWatch en 2026-08-26T06:36:00.000Z Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy https://www.biopharmawatch.com/news/YDES/yd-bio-research-publication-nutrients BiopharmaWatch en 2026-08-26T02:51:20.000Z YD Bio 宣布與台灣慢性病照護協會及未來健康研究院醫師共同撰寫的同行評審文章在 Nutrients 期刊正式發表 https://www.biopharmawatch.com/news/LLY/zepbound-lowers-healthcare-costs-adults-over-55 BiopharmaWatch en 2026-08-26T00:00:00.000Z Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study Eli Lilly and Company (NYSE: LLY) today announced results from a real-world study of adults over 55 with overweight or obesity, which found that... https://www.biopharmawatch.com/news/CELU/celularity-nasdaq-listing-compliance-update BiopharmaWatch en 2026-08-25T23:59:00.000Z Celularity Provides Update Regarding Nasdaq Listing Compliance https://www.biopharmawatch.com/news/BIIB/biogen-selects-veeva-vault-crm BiopharmaWatch en 2026-08-25T23:35:00.000Z Biogen entscheidet sich für Veeva Vault CRM https://www.biopharmawatch.com/news/SCYX/scynexis-inducement-award-nasdaq-rule-5635 BiopharmaWatch en 2026-08-25T23:06:00.000Z SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)